# Inhibitor Therapeutics, Inc. (INTI) · Edgar & Edgarette company card

> Inhibitor Therapeutics (INTI) reported revenue of $0 million in FY2021, operating margin null against a -3.8% median for pharmaceutical preparations, equity -6160% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1042418 · fiscal year ended 2021-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/INTI) · [JSON](https://www.pops4.com/boards/company/INTI.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$220,433 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $30,626 |
| Long-term debt | — |
| Total assets | $58,784 |
| Total equity | −$4M |
| Equity ÷ assets | -6159.6% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -3305.8 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$3.2M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2021). Experience: one year on record; operating margin null, up from null. Soundness: equity -6159.6% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-18 ([filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226043331/0001493152-26-043331-index.htm))

## Recent filings

- 8-K · filed 2026-09-18 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226043331/0001493152-26-043331-index.htm)
- DEF 14A · filed 2026-08-17 · [filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226038636/0001493152-26-038636-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226038288/0001493152-26-038288-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226023622/0001493152-26-023622-index.htm)
- 8-K · filed 2026-04-01 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226014637/0001493152-26-014637-index.htm)
- 8-K · filed 2026-04-01 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/0001493152-26-014517-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001042418.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1042418

## Cite

POPS4, Edgar & Edgarette: Inhibitor Therapeutics, Inc. (INTI) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/INTI. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2021, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.